No Data
No Data
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?
The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?
① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.
Viking Therapeutics, Inc. (VKTX) Advances While Market Declines: Some Information for Investors
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years